What Is Ipamorelin? What It Does and What the Evidence Shows

Written by Dr. Andrii Kaleniuk. Updated November 6, 2026.

Ipamorelin is a synthetic peptide that switches on the ghrelin receptor (the 'hunger hormone' receptor) in the brain and pituitary gland, which makes the body release a short burst of growth hormone; it was tested in people only as a treatment to speed up bowel recovery after surgery, where a Phase 2 trial missed its main goal and development was dropped. As of November 2026 there is no approved ipamorelin product anywhere in the world, there are no human studies on muscle growth, fat loss or sleep, and it is banned at all times in sport by the World Anti-Doping Agency (WADA). The FDA has flagged it as a compounding substance with significant safety risks, and an FDA advisory committee voted 0 to 12 against allowing pharmacies to compound it. This guide explains what ipamorelin does in the body, what the human evidence actually shows, where it stands legally in the US and in sport, and what independent testing has found inside 'research peptide' vials.

Ipamorelin is a pentapeptide, meaning a short chain of five amino acids. It was created by Novo Nordisk under the code NNC 26-0161 and belongs to a group of compounds called growth hormone secretagogues, which are substances that prompt the pituitary gland to release growth hormone. It works by mimicking ghrelin, a hormone made mainly in the stomach that binds to a receptor in the brain and pituitary. Ipamorelin contains amino acids that do not occur in nature, which helps it resist breakdown but, as the FDA notes, also makes the finished product harder to characterize and test.

When it was first described in 1998, researchers called it 'the first selective growth hormone secretagogue.' That label matters, and it is often misunderstood, so the next section explains it.

In a 1999 study of healthy male volunteers (eight men at each of five dose levels), an intravenous infusion of ipamorelin produced a single burst of growth hormone that peaked about 40 minutes (0.67 hours) after the start, then fell back to negligible levels. The drug's half-life, the time it takes for blood levels to halve, was about 2 hours. In other words, ipamorelin causes a short, temporary rise in growth hormone, not a sustained increase.

'Selective' refers to what it does not do. In the original animal research, older growth hormone releasing peptides such as GHRP-6 and GHRP-2 also raised ACTH and cortisol, the body's stress hormones. Ipamorelin released growth hormone without raising ACTH or cortisol and without affecting prolactin, FSH, LH or TSH. Clinic websites often turn this into 'no side effects,' but selectivity in early studies says nothing about long-term safety in people, which has never been studied. Known and reported side effects are covered in our guide to ipamorelin side effects.

How ipamorelin compares with other growth hormone peptides that work through a different receptor is discussed in sermorelin vs ipamorelin and tesamorelin vs ipamorelin.

Yes, but only for a narrow medical purpose. After abdominal surgery, the gut often stops moving normally for several days, a condition called postoperative ileus. Because ghrelin also stimulates gut movement, ipamorelin was developed as a possible treatment.

The main published trial, by Beck and colleagues in 2014, was a Phase 2, double-blind, placebo-controlled study in patients having bowel surgery. Of 117 patients enrolled, 114 were analyzed. Patients received ipamorelin or placebo intravenously twice a day for the first seven days after surgery. The main outcome was time to the first solid meal patients could tolerate: a median of 25.3 hours with ipamorelin against 32.6 hours with placebo. That difference was not statistically significant (p = 0.15), meaning it could easily have been due to chance, and none of the secondary efficacy measures differed significantly either. Side effects during treatment were common in both groups (87.5% with ipamorelin vs 94.8% with placebo), which is expected after major surgery.

Development for this use was later discontinued for lack of efficacy. No company has since run a trial of ipamorelin for growth hormone deficiency, ageing, body composition or athletic performance.

There is no human evidence that it does. We found no human trials measuring muscle mass, strength, fat loss, body composition, sleep quality or injury recovery with ipamorelin. The evidence used to support these claims comes from animal studies, such as research on bone growth and protein breakdown in rats, and from the fact that ipamorelin raises growth hormone for a short time. Even a compounding nomination submitted to the FDA, citing a 2020 review, conceded that 'clinical data on growth hormone secretagogues are largely lacking.'

A short rise in growth hormone is not the same as building muscle. Growth hormone effects depend on how long and how much it is raised, on downstream hormones such as IGF-1, and on diet and training, and none of those links has been tested with ipamorelin in people. The bodybuilding case is examined in more detail in ipamorelin for bodybuilding, and the popular combination with CJC-1295 in CJC-1295 and ipamorelin for muscle growth.

Ipamorelin is not FDA-approved for any use. Its status for pharmacy compounding, where pharmacies make medicines from raw ingredients, has changed several times, and it is easy to find outdated or misleading claims online. Here is the timeline from FDA records and legal summaries.

The FDA's stated concerns include a risk of immune reactions linked to clumping (aggregation) of the peptide and to impurities, the unnatural amino acids that make the product hard to characterize, and the absence of safety data for injection routes other than those studied. At the October 2024 meeting, committee members cited the lack of safety and efficacy data; the uses they evaluated were growth hormone deficiency and postoperative ileus.

Removal from the 503A 'safety risk' list in 2024 was not an approval: it happened only because the nomination was withdrawn, FDA's own analysis had recommended against including ipamorelin, and the advisory committee then voted unanimously against it. For how the same rules apply to another popular peptide, see is BPC-157 legal.

No. On October 28, 2026, HHS announced a draft policy, published in the Federal Register on October 30 with comments due November 13, 2026, under which FDA would not take action against pharmacies compounding six specific peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The policy applies to single-ingredient products only, so blends or 'peptide cocktails' are excluded. Ipamorelin is not on the list, and neither is CJC-1295, so the common CJC-1295 and ipamorelin blend is outside the policy on two counts. As of November 2026, nothing in that draft changes ipamorelin's status.

No. Ipamorelin is on the WADA Prohibited List under class S2 (peptide hormones, growth factors, related substances and mimetics). It is banned at all times, in and out of competition, and it is not a 'Specified Substance,' which means sanctions tend to be heavier. Sport Integrity Australia states that a therapeutic use exemption 'would not be granted' and that ipamorelin is not on Australia's register of approved medicines.

Bans have been real. In 2017, US track athlete Jason Young accepted a four-year sanction from USADA after testing positive for ipamorelin and GHRP-2. In the NBA, Wilson Chandler received a 25-game suspension in 2019. Anti-doping authorities, including the German Sport University Cologne's doping-substances list, classify it as a growth hormone secretagogue, and these sanctions show that tested athletes have been caught using it.

Ipamorelin sold online is usually labelled 'for research use only,' meaning it is not made or checked to the standards required for medicines. A preprint posted in April 2026, which has not yet been peer reviewed, analyzed 6,441 results from an independent testing service covering 14 peptides. Depending on the standard used, 41.6% to 71.1% of samples failed, and bacterial toxins (endotoxin) were found in 36 of 243 samples tested for them. All six ipamorelin reports in the dataset were flagged as not containing the stated peptide. Six samples is a very small number, but the finding fits FDA's concern about impurities and quality.

For people already using CJC-1295 and ipamorelin together, the specific risks of the blend are discussed in CJC-1295 and ipamorelin side effects, and the evidence for CJC-1295 on its own in CJC-1295 for muscle growth.

If you are comparing growth hormone peptides, our overview of tesamorelin vs CJC-1295 vs ipamorelin sets out which ones have approved uses and which do not.

Ipamorelin is a synthetic peptide that causes a short burst of growth hormone release by acting on the ghrelin receptor. Its only real-world test in patients, for gut recovery after bowel surgery, did not show a significant benefit, and development was abandoned. There is no approved product, no human evidence for muscle, fat loss or sleep, and, as of November 2026, it remains a 503B Category 2 substance that was left out of the new HHS peptide policy. It is banned in sport, and independent testing suggests that what is sold online may not even contain ipamorelin. Claims you see on clinic and vendor sites go well beyond the evidence.

This article summarizes published research and regulatory documents for general information and is not medical advice. Ipamorelin is not an approved medicine, and nothing here is a recommendation to use it.